 |
市場調查報告書
商品編碼
1890948
醫用氫可酮市場：按給藥途徑、用途、最終用戶、製造商、規格、患者年齡層、通路和地區分類Medical Morphine Market, By Route of Administration, By Application, By End User, By Manufacturing Origin, By Strength, By Patient Age Group, By Distribution Channel, By Geography |
||||||
預計到 2025 年，醫用氫可酮市場價值將達到 251.4 億美元，到 2032 年將達到 422.5 億美元，2025 年至 2032 年的複合年成長率為 7.7%。
| 報告覆蓋範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2024 | 2025年市場規模： | 251.4億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2025年至2032年 |
| 預測期（2025-2032年）複合年成長率： | 7.70% | 2032 年的預測值： | 422.5億美元 |
全球醫用氫可酮市場是製藥業的重要組成部分，主要集中在氫可酮類藥物的生產、分銷和應用，用於疼痛管理和安寧療護。氫可酮是一種植物來源的天然鴉片生物鹼，是全球臨床上治療重度疼痛的黃金標準。這種重要的治療藥物在治療急性和慢性疼痛方面發揮著至關重要的作用，尤其是在術後護理、癌症治療和臨終關懷等領域。
醫用氫可酮市場涵蓋多種劑型，包括速釋片、緩釋性製劑、注射液和口服液，每種劑型都旨在滿足特定的患者需求和臨床要求。醫療專業人員高度依賴氫可酮強大的止痛特性來改善患者的生活品質，並確保有效的疼痛管理通訊協定。市場的重要性遠不止於產生收入；它直接影響全球醫療保健成果和病患福祉。儘管面臨監管挑戰和對鴉片類藥物成癮的擔憂，醫用氫可酮因其在控制重度疼痛方面無與倫比的療效，在現代醫學中仍然不可或缺。隨著製藥技術的進步、給藥機制的改進和安全性的提升，該行業不斷發展，以在保持治療效果的同時，最大限度地降低潛在風險。
市場動態
全球醫用氫可酮市場受多種強勁因素驅動，在國際醫療保健體系中持續成長。主要促進因素包括全球慢性疼痛疾病、癌症病例和外科手術的增加，對有效的疼痛管理解決方案產生了顯著需求。全球人口老化進一步加劇了這一需求，因為老年人在整個醫療保健過程中往往需要更密集的疼痛管理介入。此外，新興經濟體醫療基礎設施的改善和疼痛管理療法的普及也顯著促進了市場擴張。醫護人員對正確疼痛管理通訊協定和病患治療舒適度重要性的認知不斷提高，也促使氫可酮在臨床應用中日益普及。
然而，該市場面臨許多限制因素，包括嚴格的鴉片類藥物處方法規結構、日益嚴重的鴉片類藥物成癮和依賴問題，以及全球監管機構日益嚴格的審查。鴉片類藥物危機導致醫療系統實施了更嚴格的處方指南，這可能會抑制市場成長。此外，替代性疼痛管理療法和非鴉片類止痛藥的出現，對傳統的氫可酮類藥物治療構成了競爭挑戰。儘管有這些限制因素，市場格局仍蘊藏著巨大的機會。開發防濫用製劑為市場成長提供了一個有前景的途徑，同時也能解決安全問題。在發展中地區擴大醫療保健服務覆蓋範圍，蘊藏著巨大的市場潛力，尤其是在疼痛管理基礎設施尚未完善的地區。
本次調查的主要特點
- 本報告對全球醫用氫可酮市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率%。
- 我們將重點介紹各個細分市場的潛在商機，並說明該市場具有吸引力的投資提案矩陣。
- 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數對全球醫用氫可酮市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告的研究結果將使負責人和經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 這份全球醫用氫可酮市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過各種用於分析全球醫用氫可酮市場的策略矩陣輕鬆做出決策。
目錄
第1章 研究目標與前提條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場範圍
- 報告概述
- 市場定義和範圍
- 執行摘要
第3章 市場動態、監管與趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 法規環境
- 產品上市及核准
- PEST分析
- 波特分析
- 併購趨勢
- 產業趨勢
4. 2020-2032年全球醫用氫可酮市場（依給藥途徑分類）
- 口服
- 腸外
- 其他給藥途徑（經皮、栓劑給藥、鼻腔給藥等）
5. 2020-2032年全球醫用氫可酮市場（依應用領域分類）
- 癌症相關疼痛管理
- 急性疼痛（術後、外傷、心肌梗塞）
- 慢性疼痛（關節炎、肌肉骨骼疾病）
- 安寧療護與臨終關懷
- 其他用途（例如，止瀉、止咳）
6. 2020-2032年全球醫用氫可酮市場（依最終用戶分類）
- 醫院和診所
- 門診手術中心
- 居家醫療/家庭保健機構
- 其他（復健中心、安寧療護中心）
7. 2020-2032年全球醫用氫可酮市場（按製造商分類）
- 品牌產品
- 非專利的
8. 2020-2032年全球醫用氫可酮市場（依濃度分類）
- 低劑量（10毫克或更少）
- 中等劑量（10毫克以上至30毫克以下）
- 高劑量（>30毫克）
9. 2020-2032年全球醫用氫可酮市場（依病患年齡層分類）
- 兒童
- 成人
- 老年人
10. 2020-2032年全球醫用氫可酮市場（依通路分類）
- 醫院藥房
- 零售藥房
- 網路藥房
11. 2020-2032年全球醫用氫可酮市場（按地區分類）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第12章 競爭格局
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Viatris Inc.
- Hikma Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Endo International plc
- Mylan NV（now Viatris）
- Merck KGaA
- Bristol Myers Squibb Company
- Grunenthal GmbH
- Sanofi SA
- AbbVie Inc.
第13章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第14章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Medical Morphine Market is estimated to be valued at USD 25.14 Bn in 2025 and is expected to reach USD 42.25 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 25.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.70% | 2032 Value Projection: | USD 42.25 Bn |
The global medical morphine market represents a critical segment within the pharmaceutical industry, primarily focused on the production, distribution, and utilization of morphine-based medications for pain management and palliative care. Morphine, a naturally occurring opioid alkaloid derived from the opium poppy plant, serves as the gold standard for severe pain relief in clinical settings worldwide. This essential therapeutic agent plays an indispensable role in managing acute and chronic pain conditions, particularly in post-surgical care, cancer treatment, and end-of-life care scenarios.
The medical morphine market encompasses various formulations including immediate-release tablets, extended-release formulations, injectable solutions, and oral liquids, each designed to meet specific patient needs and clinical requirements. Healthcare providers rely heavily on morphine's potent analgesic properties to improve patient quality of life and ensure effective pain management protocols. The market's significance extends beyond mere revenue generation, as it directly impacts global healthcare outcomes and patient welfare. Despite regulatory challenges and concerns surrounding opioid dependency, medical morphine remains irreplaceable in modern medicine due to its unparalleled efficacy in severe pain management. The industry continues to evolve with advancing pharmaceutical technologies, improved delivery mechanisms, and enhanced safety profiles to maintain therapeutic benefits while minimizing potential risks.
Market Dynamics
The global medical morphine market is driven by several compelling factors that sustain its growth trajectory across international healthcare systems. The primary driver stems from the increasing prevalence of chronic pain conditions, cancer cases, and surgical procedures worldwide, creating substantial demand for effective pain management solutions. An aging global population further amplifies this demand, as elderly individuals typically require more intensive pain management interventions throughout their healthcare journey. Additionally, improved healthcare infrastructure in emerging economies and enhanced access to pain management therapies contribute significantly to market expansion. Growing awareness among healthcare professionals regarding proper pain management protocols and the importance of patient comfort during treatment has led to increased morphine utilization in clinical settings.
However, the market faces considerable restraints including stringent regulatory frameworks governing opioid prescriptions, growing concerns about opioid addiction and dependency, and increasing scrutiny from regulatory authorities worldwide. The opioid crisis has prompted healthcare systems to implement more restrictive prescribing guidelines, potentially limiting market growth. Furthermore, the emergence of alternative pain management therapies and non-opioid analgesics presents competitive challenges to traditional morphine-based treatments. Despite these restraints, significant opportunities exist within the market landscape. The development of abuse-deterrent formulations presents promising avenues for market growth while addressing safety concerns. Expanding healthcare access in developing regions offers untapped market potential, particularly in areas where pain management infrastructure is still developing.
Key Features of the Study
- This report provides in-depth analysis of the global medical morphine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global medical morphine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals plc, Sun Pharmaceutical Industries Ltd., Johnson and Johnson, Viatris Inc., Hikma Pharmaceuticals plc, Aurobindo Pharma Ltd., Endo International plc, Mylan N.V. (now Viatris), Merck KGaA, Bristol Myers Squibb Company, Grunenthal GmbH, Sanofi S.A., and AbbVie Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global medical morphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global medical morphine market
Market Segmentation
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Other routes (transdermal, suppository, intranasal, etc.)
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Cancer related pain management
- Acute pain (post surgery, trauma, myocardial infarction)
- Chronic pain (arthritis, musculoskeletal disorders)
- Palliative and end of life care
- Other applications (e.g., diarrhea suppression, cough suppression)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Homecare/Home Healthcare Settings
- Other (rehabilitation centers, hospices)
- Manufacturing Origin Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Strength Insights (Revenue, USD Bn, 2020 - 2032)
- Low dose (e.g.<=10 mg)
- Medium dose (e.g.10 mg to <=30 mg)
- High dose (30 mg)
- Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Viatris Inc.
- Hikma Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Endo International plc
- Mylan N.V. (now Viatris)
- Merck KGaA
- Bristol Myers Squibb Company
- Grunenthal GmbH
- Sanofi S.A.
- AbbVie Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Medical Morphine Market, By Route of Administration
- Global Medical Morphine Market, By Application
- Global Medical Morphine Market, By End User
- Global Medical Morphine Market, By Manufacturing Origin
- Global Medical Morphine Market, By Strength
- Global Medical Morphine Market, By Patient Age Group
- Global Medical Morphine Market, By Distribution Channel
- Global Medical Morphine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Medical Morphine Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes (transdermal, suppository, intranasal, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Medical Morphine Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cancer related pain management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Acute pain (post surgery, trauma, myocardial infarction)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Chronic pain (arthritis, musculoskeletal disorders)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Palliative and end of life care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other applications (e.g., diarrhea suppression, cough suppression)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Medical Morphine Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare/Home Healthcare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other (rehabilitation centers, hospices)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Medical Morphine Market, By Manufacturing Origin, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Medical Morphine Market, By Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Low dose (e.g.<=10 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Medium dose (e.g.>10 mg to <=30 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- High dose (>30 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Medical Morphine Market, By Patient Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Medical Morphine Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Medical Morphine Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Origin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V. (now Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grunenthal GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
氫可酮市場規模、佔有率和成長分析（按形式、分銷管道、應用、最終用戶和地區）- 2025-2032 年產業預測
嗎啡藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、應用、地區和競爭細分，2019-2029F![嗎啡藥物市場規模 - 按劑型（注射、口服）、應用（疼痛管理 [癌症、神經性、骨關節炎]、安寧療護、止瀉藥、感冒和咳嗽、麻醉）、配銷通路、最終用途和預測，2024年 - 2032](/sample/img/cover/42/default_cover_gmi.png)
嗎啡藥物市場規模 - 按劑型（注射、口服）、應用（疼痛管理 [癌症、神經性、骨關節炎]、安寧療護、止瀉藥、感冒和咳嗽、麻醉）、配銷通路、最終用途和預測，2024年 - 2032
嗎啡藥物市場，按劑型、按應用、配銷通路、最終用途、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測嗎啡市場報告：2030 年趨勢、預測與競爭分析